Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | PYGM | P11217 | 3/20 | 0.40 |
| ▸ | TYMP | P19971 | 2/20 | 0.38 |
| ▸ | TK2 | O00142 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955997 | 1.00 | LMNA (0.47) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL4952184 | 1.00 | LMNA (0.47) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL4948622 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL12150939 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL4952908 | 0.82 | SLC28A1 (0.54) | P2RY6P2RY14 | |
| SCHEMBL4953147 | 0.80 | P2RY6 (0.36) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL5637213 | 0.80 | P2RY6 (0.36) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL26268007 | 0.79 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL23590367 | 0.78 | LMNA (0.59) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL10888417 | 0.78 | LMNA (0.59) | LMNASMN1; SMN2TSHRMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284741-B1 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1964569-A2 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections | Pharmasset, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7094770-B2 | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections | PHARMASSET, LTD. (BB) | 2006-08-22 | — | — | US | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | LMNA 1253/4885SMN1; SMN2 2618/4885TSHR 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.